Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DWJ1718
- Development stage
- Unknown
- Lead developer
- Great Bear Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWJ1718 is an investigational oral solid dosage form medication being developed by Daewoong Pharmaceutical (also known as Great Bear Pharmaceutical) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). It is classified as an incrementally modified drug (IMD), specifically a new formulation of methylphenidate hydrochloride. The drug is designed to provide a controlled or extended release of the active ingredient to improve therapeutic efficacy and patient adherence compared to existing formulations. DWJ1718 acts as a stimulant by inhibiting the reuptake of dopamine and norepinephrine in the central nervous system, thereby increasing their availability in the synaptic cleft. The program has progressed into Phase 3 clinical development in South Korea.
Beyond the preview
Go deeper on DWJ1718.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DWJ1718.